Drug Indication

Key facts

Label location

Section 1, Indications and Usage, of the prescribing information

Regulation

21 CFR 201.57(c)(2)

New indications added by

Efficacy supplement to an NDA or BLA

Medicaid and Part D standard

Medically accepted indication: FDA-approved or compendia-supported use

What is a drug indication?

An indication describes what a drug is approved to treat, prevent, mitigate or diagnose, and often for whom: an age group, disease stage, biomarker status or line of therapy. A cancer drug, for example, may be indicated only for adults whose tumors carry a specific marker after prior treatment.

Indications are granted one at a time. A drug first approved for one condition can gain new indications when the sponsor submits clinical evidence, and a generic may omit indications still protected by patents or exclusivity.

An indication is not the same as a use. Clinicians may prescribe for uses outside the labeled indications, known as off-label use, but manufacturer promotion is limited to approved uses.

How indications are added and changed

The indication list on a label changes over a product lifecycle:

• Original approval: a New Drug Application (NDA) or Biologics License Application (BLA) establishes the first indications, supported by adequate and well-controlled studies.
• Efficacy supplements: a supplemental application adds a new indication, patient population or dosing regimen.
• Accelerated approval: an indication approved on a surrogate endpoint requires confirmatory trials and can be withdrawn if clinical benefit is not confirmed.
• Orphan status: orphan drug designation and exclusivity attach to specific rare disease uses rather than to the drug as a whole.
• Removal: an indication can be withdrawn by the sponsor or the FDA, and the label is revised.

Why drug indications matter

Indications set the boundaries of a drug market:

• Market sizing: the approved indication defines the addressable patient population in revenue forecasts, and each new indication expands it.
• Coverage: Medicaid and Medicare Part D pay for drugs used for medically accepted indications, meaning FDA-approved uses or uses supported by specified drug compendia.
• Competitive analysis: two drugs with the same mechanism may compete only where their indications overlap, such as a specific line of therapy.
• Data joins: label indications are free text, so linking them to ClinicalTrials.gov conditions or claims diagnoses requires mapping to vocabularies such as MeSH or ICD-10-CM.